Actively Recruiting
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
Led by Peking University Cancer Hospital & Institute · Updated on 2024-04-22
111
Participants Needed
1
Research Sites
221 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multicenter, randomized, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib (cohort 1), or Adebrelimab plus Bevacizumab (cohort 2), or Camrelizumab plus Apatinib (cohort 3) as first-line treatment of unresectable HCC.
CONDITIONS
Official Title
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Locally advanced or metastatic and/or unresectable Hepatocellular Carcinoma (HCC)
- No prior systemic therapy for HCC; prior use of herbal therapies/traditional Chinese medicines with anti-cancer activity allowed
- BCLC stage B or C, not suitable for surgical or local therapy, or progressed after surgery/local therapy
- At least one measurable lesion per RECIST v1.1
- ECOG Performance Status of 0 or 1
- Child-Pugh class A5 to B7
- Adequate organ function
You will not qualify if you...
- Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma, lamellar cell carcinoma, or other active malignant tumors within 5 years or simultaneously
- Moderate-to-severe ascites with clinical symptoms
- History of gastrointestinal hemorrhage within 6 months prior to study treatment or bleeding tendency
- Abdominal fistula, gastrointestinal perforation, or intraperitoneal abscess within 6 months prior to study treatment
- Known genetic or acquired hemorrhage or thrombotic tendency
- Thrombosis or thromboembolic event within 6 months prior to study treatment
- Uncontrolled hypertension despite antihypertensive treatment
- Factors affecting oral drug administration
- History of hepatic encephalopathy
- Previous or current metastasis to the central nervous system
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
Research Team
J
Jun Zhou
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here